LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5906 | 5578 | 1.0588 | 1.1081 |
| SK-BR-3 | GSK1059615 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5115 | 5578 | 0.9169 | 0.8472 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4735 | 5578 | 0.8489 | 0.7223 |
| SK-BR-3 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 1901 | 5578 | 0.3408 | -0.2116 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4310 | 5578 | 0.7727 | 0.5822 |
| SK-BR-3 | GW843682X | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5028 | 5578 | 0.9014 | 0.8187 |
| SK-BR-3 | HG-5-113-01 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5446 | 5578 | 0.9762 | 0.9563 |
| SK-BR-3 | HG-5-88-01 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 3697 | 5578 | 0.6628 | 0.3803 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5620 | 5578 | 1.0075 | 1.0138 |
| SK-BR-3 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4474 | 5578 | 0.8021 | 0.6363 |
| SK-BR-3 | JW-7-24-1 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4184 | 5578 | 0.7501 | 0.5407 |
| SK-BR-3 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2334 | 5578 | 0.4184 | -0.0689 |
| SK-BR-3 | LDN-193189 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5730 | 5578 | 1.0272 | 1.0500 |
| SK-BR-3 | Linifanib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5610 | 5578 | 1.0057 | 1.0105 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 4345 | 5578 | 0.7789 | 0.5936 |
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP5 | 72 | hr | 2543 | 2003 | 5578 | 0.3591 | -0.1781 |
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP6 | 72 | hr | 2543 | 1620 | 5578 | 0.2905 | -0.3041 |
| SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4652 | 5578 | 0.8339 | 0.6947 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 1625 | 5578 | 0.2914 | -0.3025 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6242 | 5578 | 1.1190 | 1.2188 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5779 | 5578 | 1.0359 | 1.0660 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 5767 | 5578 | 1.0338 | 1.0620 |
| SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 2638 | 5578 | 0.4729 | 0.0313 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5710 | 5578 | 1.0237 | 1.0435 |
| SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 4893 | 5578 | 0.8771 | 0.7741 |